This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read INmune Bio’s 8K filing here.
About INmune Bio
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Read More
- Five stocks we like better than INmune Bio
- Investing in Travel Stocks Benefits
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- Breakout Stocks: What They Are and How to Identify Them
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- 3 Monster Growth Stocks to Buy Now
- Top Nuclear Stocks Thriving on Soaring Energy Demand
